Scinai Immunotherapeutics Ltd.

SCNI

$1.94

-0.51%

N/A-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in ...

Fundamental Analysis of SCNI

Key Strengths

NanoAb (VHH antibody fragment) platform focused on immunology/inflammation, offering a differentiated therapeutic modality if clinical efficacy is demonstrated

Strategic licensing/collaboration framework (e.g., Max Planck Society and University Medical Center Göttingen) that can improve scientific credibility and pipeline momentum

Risk Factors

Sustained profitability risk: deeply negative margins (net margin ~-1.9%, operating/EBIT margins ~-5% to -7%) indicate ongoing operating losses

Cash-flow burn: negative operating cash flow and materially negative free cash flow suggest reliance on future financing, milestones, or improved CDMO economics

Profitability

Net Margin-176.96%

Operating Margin-563.89%

Valuation

P/E Ratio-0.00x

Current Ratio1.56

Efficiency

ROE-26.63%

ROA-15.39%

Fundamental Analysis of SCNI

Scinai Immunotherapeutics (SCNI) is an early-stage Israeli biopharmaceutical company (Nasdaq: Capital Market) focused on developing immunology/inflammation therapies using NanoAb (VHH antibody fragment) technology, while also providing boutique CDMO services. Fundamental performance in the latest available TTM snapshot is characterized by persistent losses and weak cash generation. Margins are deeply negative: gross margin is approximately -2.2% and net margin is about -1.9%, with operating/EBIT margins around -5.7% and -6.5% respectively. Returns are similarly negative (ROE roughly -29.8% and ROA roughly -15.2%), consistent with a company still investing heavily relative to revenue. On balance-sheet liquidity, the firm appears to have near-term working-capital support: current ratio is about 1.35 and quick ratio about 1.35, suggesting it can cover near-term obligations better than many pre-revenue or early-revenue biotech peers. Leverage is not extreme on the provided metrics (debt-to-equity ~0.30; net debt-to-EBITDA near zero), which reduces immediate solvency risk. However, cash flow quality remains a key issue: TTM free cash flow and operating cash flow indicators are negative (enterprise value to operating cash flow and free cash flow are both negative in the snapshot), implying ongoing reliance on external funding, capital raises, or milestone-driven inflows rather than internally generated cash. Valuation multiples provided are not meaningfully interpretable because earnings and cash flow are negative (e.g., P/E and EV/FCF distort toward zero or negative values). Price-to-sales is around ~3.0x, which is directionally plausible for small-cap biotech if growth or milestones materialize, but it does not compensate for the current lack of profitability. Competitive/strategic positioning is best understood via its NanoAb platform partnerships (Max Planck Society and University Medical Center Göttingen) and its ability to offer end-to-end development/manufacturing services. Nonetheless, analyst sentiment for small biotech is highly dependent on clinical and regulatory progress; without demonstrated efficacy, the probability-weighted outcomes remain uncertain. Overall, SCNI’s fundamentals indicate a speculative, development-stage profile: reasonable liquidity for now, limited leverage risk, but clear profitability and cash-flow challenges. For long-term investors, the core question is whether NanoAb program milestones and/or CDMO revenue scale can convert the current burn rate into sustainable growth and positive operating leverage.

Key Strengths of SCNI

NanoAb (VHH antibody fragment) platform focused on immunology/inflammation, offering a differentiated therapeutic modality if clinical efficacy is demonstrated
Strategic licensing/collaboration framework (e.g., Max Planck Society and University Medical Center Göttingen) that can improve scientific credibility and pipeline momentum
Boutique CDMO capability (process development, scale-up, and GMP manufacturing support) that can diversify revenue beyond single-asset development
Liquidity appears adequate for near-term operations (current ratio and quick ratio ~1.35 in the latest TTM snapshot)
Moderate balance-sheet leverage based on debt-to-equity (~0.30), reducing immediate financial distress risk relative to more highly levered peers
Small-cap flexibility: ability to reallocate resources quickly across trials, formulations, or CDMO capacity as data emerges

Risk Factors of SCNI

Sustained profitability risk: deeply negative margins (net margin ~-1.9%, operating/EBIT margins ~-5% to -7%) indicate ongoing operating losses
Cash-flow burn: negative operating cash flow and materially negative free cash flow suggest reliance on future financing, milestones, or improved CDMO economics
Clinical development and regulatory uncertainty: NanoAbs’ therapeutic potential may not be met; delays in preclinical/clinical data can impair value creation
Financing/dilution risk: typical biotech funding needs can dilute shareholders through equity issuance or similar instruments
CDMO demand volatility risk: lower-than-anticipated CDMO revenues (or slower client conversion to manufacturing) could worsen cash burn
Small company risk: limited diversification of programs and potential concentration in a few indications/partners
Macro/sector risk: biotech funding cycles and investor risk appetite can tighten, increasing cost and reducing availability of capital

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$1.00M

-0.0x

P/E Ratio

0.7x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin-252.45%

Net Profit Margin-176.96%

Debt/Equity Ratio0.31

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of SCNI

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of SCNI

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	-435.44%	—	—	Flat
Operating Margin	—	-466.52%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of SCNI

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	1.563	—	—	Flat
Quick Ratio	—	1.563	—	—	Flat
Debt / Equity	—	0.305	—	—	Flat

Valuation of SCNI

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-0.40x	—	—	Flat
P/B	—	12.29x	—	—	Flat

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer